The role of tumor molecular subtypes in formation of personalized approach to the theatment of breast cancer.

Authors

  • I. N. Bondarenko
  • Mohammad H. Elhajj
  • K. O. Chebanov
  • A. V. Phokhach
  • Y. N. Bondarenko

DOI:

https://doi.org/10.26641/2307-0404.2016.2.72161

Keywords:

breast cancer, molecular subtype, heterogeneity, individualization, immunohistochemical testing

Abstract

Extreme heterogeneity of breast cancer (BC) is considered to be one of the reasons that affects the success of treatment. According to current classifications, there are 4 molecular subtypes (MS). The basis forsubtypes division is immunohistochemical testing of tumor cell receptors - estrogen (ER), progesterone (PR), HER2-neu and Ki-67. The doctrine of the tumor MS was the basis for the individualization of therapeutic tactics in patients with breast cancer. It was studied that luminal A subtype is the most common and the most favorable, with hormone therapy being a highly effective treatment method. Luminal B subtype, HER2 - positive and triple negative MSis characterized by a high ag­gressiveness, worse survival rate of patients and better prognostic effect of chemotherapy. The importance of determining the level of Ki-67 for assessment of tumor aggressiveness was revealed. Significant differences in receptor status of the primary tumor and metastases were proven. Data on the impact of changes in receptor status of the tumor prognosis are ambiguous and need further study. The use of targeted agents in the treatment of HER2 + patients can significantly improve treatment outcomes, turning this MS from historically aggressive subgroup to quite favorable.

Author Biographies

I. N. Bondarenko

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of oncology and medical radiology
Dzerzhinsky str., 9, Dnipropetrovsk, 49044, Ukraine

Mohammad H. Elhajj

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of oncology and medical radiology
Dzerzhinsky str., 9, Dnipropetrovsk, 49044, Ukraine

K. O. Chebanov

ME «Dnipropetrovsk City Multidisciplinary Hospital N 4» DRC
Blygnia str., 31, Dnipropetrovsk, 49000, Ukraine

A. V. Phokhach

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of oncology and medical radiology
Dzerzhinsky str., 9, Dnipropetrovsk, 49044, Ukraine

Y. N. Bondarenko

SE «Dnipropetrovsk medical academy of Health Ministry of Ukraine»
Department of oncology and medical radiology
Dzerzhinsky str., 9, Dnipropetrovsk, 49044, Ukraine

References

Shchepotin IB, Zotov AS, Lyubota RV. [Molecu-lar subtypes of breast cancer determined by immuno-histochemistry markers: clinical, biology aspects and prognosis]. Opukholi grudnoy zhelezy. 2012;8(4):388. Russian.

Perevodchikova N.I., Stenina M.B. [Guidelines for chemotherapy of neoplastic diseases]. Praktica. 2014;238. Russian.

Slamon D, Eierman W, Robert N. Brest Cancer International Research Group. Adjuvant trastuzumab in HER-2 positive breast cancer. N Engl J Med. 2011;365:1273-83.

Aleix P, Estela P. Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast. 2015;24(2):26–35.

Cataliotti L, Buzdar A. Comparison of anastro-zole versus tamoxifen as preoperative therapy in post-menopausal women with hormone receptor –positive breast cancer: the Pre- Operative “Arimidex” Compared to Tamoxifen (PROACT) trial . Cancer. 2006;106:2095-103.

Perez E, Romond E, Suman V. Four –year follow- up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2- positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B -31. J Clin Jncol. 2011;29:3366-73.

Carvalho F, Bacchi L, Pincerato K. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102.

Chin K. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006; 10:529–541.

Goldhirsch F, Winer E, Coates A. Personalizing the treatment of women with early breast cancer: hig-hlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Ocol. 2013;24:2206-23.

Haquе R, Syed A, Inzhakova G. Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades. Cancer Epidemiol Biomarkers Prev. 2012;21:379.

Yu K, Wu J, Shen Z, Shao Z. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy. J Clin Endocrinol Metab. 2012;97:E2201-9.

Makretsov N, Huntsman D, Nielsen T. Hierarchi-cal clustering analysis of tissue microarray immuno-staining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res. 2004;10:6143-51.

Siew K, Moo H, In Hae P. Impact of Molecular Subtype Conversion of Breast Cancers after Neoadjuvant Chemotherapy on Clinical Outcome. Cancer Research and Treatment: Official Journal of Korean Cancer Association. 2015;362:2.

Ky C, Martelotto L. Intra-tumor genetic hetero-geneity and alternative driver genetic alterations in breast cancers with heterogeneousHER2 gene amplification. Genome Biology. 2015;16:107.

Engstrøm M, Opdahl S, Hagen A. Molecular subtypes, histopathological grade and survival in a his¬to-ric cohort of breast cancer patients. Preclinical Study Breast Cancer Research and Treatment. 2013;140(3):463-73.

Dawood S, Broglio K, Buzdar A. Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Re-view. 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL., May 30-June 3. 2008;366: 8.

Martínez E, Hernández A, Zotano Á. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. Springer International Publishing AG Breast Cancer Research and Treatment. 2014;143(3):507-15.

Siegel R, Naishadham D, Jemal A. Cancer sta-tistics. CA: a cancer journal for clinicians. 2013;63:11.

Carey A, Dees E, Sawyer l. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Oncol Res. 2007;3:2329-34.

Zahir S, Ezatollah A, Barand P. Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes. Medicine (Baltimore). 2015;94(32):1359.

Zhou W, Jirström K, Amini R. Molecular sub¬types in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.BMC Cancer. 2013;13:512.

Downloads

Published

2016-05-31

How to Cite

1.
Bondarenko IN, Elhajj MH, Chebanov KO, Phokhach AV, Bondarenko YN. The role of tumor molecular subtypes in formation of personalized approach to the theatment of breast cancer. Med. perspekt. [Internet]. 2016May31 [cited 2024Jun.21];21(2):81-6. Available from: https://journals.uran.ua/index.php/2307-0404/article/view/72161

Issue

Section

CLINICAL MEDICINE